364 related articles for article (PubMed ID: 26983776)
1. Selection of optimal chelator improves the contrast of GRPR imaging using bombesin analogue RM26.
Mitran B; Varasteh Z; Selvaraju RK; Lindeberg G; Sörensen J; Larhed M; Tolmachev V; Rosenström U; Orlova A
Int J Oncol; 2016 May; 48(5):2124-34. PubMed ID: 26983776
[TBL] [Abstract][Full Text] [Related]
2. The effect of macrocyclic chelators on the targeting properties of the 68Ga-labeled gastrin releasing peptide receptor antagonist PEG2-RM26.
Varasteh Z; Mitran B; Rosenström U; Velikyan I; Rosestedt M; Lindeberg G; Sörensen J; Larhed M; Tolmachev V; Orlova A
Nucl Med Biol; 2015 May; 42(5):446-454. PubMed ID: 25684649
[TBL] [Abstract][Full Text] [Related]
3. Selection of an optimal macrocyclic chelator improves the imaging of prostate cancer using cobalt-labeled GRPR antagonist RM26.
Mitran B; Thisgaard H; Rinne S; Dam JH; Azami F; Tolmachev V; Orlova A; Rosenström U
Sci Rep; 2019 Nov; 9(1):17086. PubMed ID: 31745219
[TBL] [Abstract][Full Text] [Related]
4. Synthesis and characterization of a high-affinity NOTA-conjugated bombesin antagonist for GRPR-targeted tumor imaging.
Varasteh Z; Velikyan I; Lindeberg G; Sörensen J; Larhed M; Sandström M; Selvaraju RK; Malmberg J; Tolmachev V; Orlova A
Bioconjug Chem; 2013 Jul; 24(7):1144-53. PubMed ID: 23763444
[TBL] [Abstract][Full Text] [Related]
5. In vitro and in vivo evaluation of a (18)F-labeled high affinity NOTA conjugated bombesin antagonist as a PET ligand for GRPR-targeted tumor imaging.
Varasteh Z; Aberg O; Velikyan I; Lindeberg G; Sörensen J; Larhed M; Antoni G; Sandström M; Tolmachev V; Orlova A
PLoS One; 2013; 8(12):e81932. PubMed ID: 24312607
[TBL] [Abstract][Full Text] [Related]
6. Preclinical Evaluation of the Copper-64 Labeled GRPR-Antagonist RM26 in Comparison with the Cobalt-55 Labeled Counterpart for PET-Imaging of Prostate Cancer.
Baun C; Mitran B; Rinne SS; Dam JH; Olsen BB; Tolmachev V; Orlova A; Thisgaard H
Molecules; 2020 Dec; 25(24):. PubMed ID: 33352838
[TBL] [Abstract][Full Text] [Related]
7. Trastuzumab cotreatment improves survival of mice with PC-3 prostate cancer xenografts treated with the GRPR antagonist
Mitran B; Rinne SS; Konijnenberg MW; Maina T; Nock BA; Altai M; Vorobyeva A; Larhed M; Tolmachev V; de Jong M; Rosenström U; Orlova A
Int J Cancer; 2019 Dec; 145(12):3347-3358. PubMed ID: 31077356
[TBL] [Abstract][Full Text] [Related]
8. The effect of mini-PEG-based spacer length on binding and pharmacokinetic properties of a 68Ga-labeled NOTA-conjugated antagonistic analog of bombesin.
Varasteh Z; Rosenström U; Velikyan I; Mitran B; Altai M; Honarvar H; Rosestedt M; Lindeberg G; Sörensen J; Larhed M; Tolmachev V; Orlova A
Molecules; 2014 Jul; 19(7):10455-72. PubMed ID: 25036155
[TBL] [Abstract][Full Text] [Related]
9. A new (68)Ga-labeled BBN peptide with a hydrophilic linker for GRPR-targeted tumor imaging.
Pan D; Xu YP; Yang RH; Wang L; Chen F; Luo S; Yang M; Yan Y
Amino Acids; 2014 Jun; 46(6):1481-9. PubMed ID: 24633452
[TBL] [Abstract][Full Text] [Related]
10. High Contrast PET Imaging of GRPR Expression in Prostate Cancer Using Cobalt-Labeled Bombesin Antagonist RM26.
Mitran B; Thisgaard H; Rosenström U; Dam JH; Larhed M; Tolmachev V; Orlova A
Contrast Media Mol Imaging; 2017; 2017():6873684. PubMed ID: 29097932
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of a novel GRPR antagonist for prostate cancer PET imaging: [
Mansour N; Paquette M; Ait-Mohand S; Dumulon-Perreault V; Guérin B
Nucl Med Biol; 2018 Jan; 56():31-38. PubMed ID: 29154145
[TBL] [Abstract][Full Text] [Related]
12.
Rinne SS; Abouzayed A; Gagnon K; Tolmachev V; Orlova A
Sci Rep; 2021 Feb; 11(1):3631. PubMed ID: 33574368
[TBL] [Abstract][Full Text] [Related]
13. Receptor-binding, biodistribution, dosimetry, and micro-SPECT/CT imaging of 111In-[DTPA(1), Lys(3), Tyr(4)]-bombesin analog in human prostate tumor-bearing mice.
Ho CL; Chen LC; Lee WC; Chiu SP; Hsu WC; Wu YH; Yeh CH; Stabin MG; Jan ML; Lin WJ; Lee TW; Chang CH
Cancer Biother Radiopharm; 2009 Aug; 24(4):435-43. PubMed ID: 19694578
[TBL] [Abstract][Full Text] [Related]
14. Positron Emission Tomography Imaging of Prostate Cancer with Ga-68-Labeled Gastrin-Releasing Peptide Receptor Agonist BBN
Cheng S; Lang L; Wang Z; Jacobson O; Yung B; Zhu G; Gu D; Ma Y; Zhu X; Niu G; Chen X
Bioconjug Chem; 2018 Feb; 29(2):410-419. PubMed ID: 29254329
[TBL] [Abstract][Full Text] [Related]
15. PEGylation of (99m)Tc-labeled bombesin analogues improves their pharmacokinetic properties.
Däpp S; García Garayoa E; Maes V; Brans L; Tourwé DA; Müller C; Schibli R
Nucl Med Biol; 2011 Oct; 38(7):997-1009. PubMed ID: 21982571
[TBL] [Abstract][Full Text] [Related]
16. Dual-Modality Imaging of Prostate Cancer with a Fluorescent and Radiogallium-Labeled Gastrin-Releasing Peptide Receptor Antagonist.
Zhang H; Desai P; Koike Y; Houghton J; Carlin S; Tandon N; Touijer K; Weber WA
J Nucl Med; 2017 Jan; 58(1):29-35. PubMed ID: 27516447
[TBL] [Abstract][Full Text] [Related]
17. Bombesin antagonist-based radioligands for translational nuclear imaging of gastrin-releasing peptide receptor-positive tumors.
Abiraj K; Mansi R; Tamma ML; Fani M; Forrer F; Nicolas G; Cescato R; Reubi JC; Maecke HR
J Nucl Med; 2011 Dec; 52(12):1970-8. PubMed ID: 22080443
[TBL] [Abstract][Full Text] [Related]
18. Bombesin analogues for gastrin-releasing peptide receptor imaging.
Nanda PK; Pandey U; Bottenus BN; Rold TL; Sieckman GL; Szczodroski AF; Hoffman TJ; Smith CJ
Nucl Med Biol; 2012 May; 39(4):461-71. PubMed ID: 22261143
[TBL] [Abstract][Full Text] [Related]
19. In vitro and in vivo evaluation of a 64Cu-labeled NOTA-Bn-SCN-Aoc-bombesin analogue in gastrin-releasing peptide receptor expressing prostate cancer.
Craft JM; De Silva RA; Lears KA; Andrews R; Liang K; Achilefu S; Rogers BE
Nucl Med Biol; 2012 Jul; 39(5):609-16. PubMed ID: 22261146
[TBL] [Abstract][Full Text] [Related]
20. N-terminal modifications improve the receptor affinity and pharmacokinetics of radiolabeled peptidic gastrin-releasing peptide receptor antagonists: examples of 68Ga- and 64Cu-labeled peptides for PET imaging.
Gourni E; Mansi R; Jamous M; Waser B; Smerling C; Burian A; Buchegger F; Reubi JC; Maecke HR
J Nucl Med; 2014 Oct; 55(10):1719-25. PubMed ID: 25146125
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]